Human RP105 monoclonal antibody enhances antigen-specific antibody production in unique culture conditions
Tatsuya Yamazaki
(Department of Microbiology and Immunology, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan)
Kenta Iwasaki
(Department of Kidney Diseases and Transplant Immunology, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan; Corresponding author)
Susumu Tomono
(Department of Microbiology and Immunology, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan)
Masaki Imai
(Department of Medical Technology and Sciences, Kyoto Tachibana University, Kyoto, Kyoto, Japan)
Yuko Miwa
(Department of Kidney Diseases and Transplant Immunology, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan)
Masato Shizuku
(Department of Renal Transplant Surgery, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan)
Satoshi Ashimine
(Department of Renal Transplant Surgery, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan)
Kohei Ishiyama
(Department of Renal Transplant Surgery, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan)
Masanori Inui
(Department of Microbiology and Immunology, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan)
Daisuke Okuzaki
(Laboratory of Human Immunology (Single Cell Genomics), WPI-IFReC, Osaka University, Suita, Osaka, Japan)
Manabu Okada
(Department of Transplant and Endocrine Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Aichi, Japan)
Takaaki Kobayashi
(Department of Renal Transplant Surgery, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan)
Sachiko Akashi-Takamura
(Department of Microbiology and Immunology, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan; Corresponding author)
Journal: iScience
•
• Elsevier
• ISSN: 2589-0042
Abstract
Summary: Detecting antibodies, particularly those targeting donor human leukocyte antigens in organ transplantation and self-antigens in autoimmune diseases, is crucial for diagnosis and therapy. Radioprotective 105 (RP105), a Toll-like receptor family protein, is expressed in immune-competent cells, such as B cells. Studies in mice have shown that the anti-mouse RP105 antibody strongly activates B cells and triggers an adjuvant effect against viral infections. However, the anti-human RP105 antibody (ɑhRP105) weakly activates human B cells. This study established new culture conditions under, which human B cells are strongly activated by the ɑhRP105. When combined with CpGDNA, specific antibody production against blood group carbohydrates, ɑGal, and SARS-CoV-2 was successfully detected in human B cell cultures. Furthermore, comprehensive analysis using liquid chromatography-electrospray ionization tandem mass spectrometry, single-cell RNA sequencing, and quantitative real-time PCR revealed that ɑhRP105 triggered a different activation stimulus compared to CpGDNA. These findings could help identify antibody-producing B cells in cases of transplant rejection and autoimmune diseases.